Sartorius Stedim Biotech S.A. (OTCMKTS:SDMHF – Get Free Report)’s stock price was up 5.5% during trading on Friday . The stock traded as high as $229.00 and last traded at $229.00. 90 shares traded hands during trading, a decline of 96% from the average session volume of 2,051 shares. The stock had previously closed at $217.09.
Wall Street Analyst Weigh In
Separately, UBS Group raised Sartorius Stedim Biotech to a “buy” rating in a research note on Thursday, August 20th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Sartorius Stedim Biotech currently has a consensus rating of “Moderate Buy”.
View Our Latest Analysis on SDMHF
Sartorius Stedim Biotech Stock Up 5.5%
About Sartorius Stedim Biotech
Sartorius Stedim Biotech SA (OTCMKTS: SDMHF) is a global provider of bioprocessing equipment and services for the biopharmaceutical industry. The company develops and manufactures technologies that support the development and production of vaccines, monoclonal antibodies, therapeutic proteins and cell‐ and gene‐based therapies. Its solutions address both upstream processes—such as cell cultivation and fermentation—and downstream processes, including filtration, centrifugation and chromatography.
Key product offerings include single‐use bioreactors and mixers, modular filtration assemblies, prepacked chromatography columns, and a wide range of cell culture media and buffer systems.
Further Reading
- Five stocks we like better than Sartorius Stedim Biotech
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Sartorius Stedim Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius Stedim Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
